The National Healthcare Security Administration (NHSA) has released a notification indicating that the expert review process for the selection of drugs eligible to enter the price negotiation process as part of this year’s update to the National Reimbursement Drug List (NRDL) has been completed. This marks a significant step in the annual update process for the NRDL.
Review Process and Drug Selection
Previously, it was reported that NHSA’s experts considered a total of 343 drugs for entry into the NRDL this year, though the final selection number has not been disclosed at this stage. Last year, 271 drugs entered the expert review stage, with 117 proceeding to the final negotiations stage. This year’s results are categorized as “new drug products to be negotiated,” “new indications to be negotiated,” “to be renewed after re-negotiation,” and “to be renewed based on simplified procedures.”
Next Steps for Manufacturers
Relevant manufacturers are advised to download, fill out, and submit the “Confirmation Letter Template” before October 20, 2022, with original versions to be mailed to the NHSA. Those confirmed for negotiation and bidding participation are asked to download, fill out, and submit the “Filings Template” before November 3, 2022, with filings in the forms of paper and electronic CDs mailed to the NHSA. Applicants are not allowed to disclose any adjustment information before the official publication of the 2022 NRDL.
Future Outlook
The completion of the expert review process underscores the NHSA’s commitment to ensuring that the NRDL includes essential drugs at accessible prices. By finalizing the selection of drugs for negotiation, the NHSA aims to enhance the availability and affordability of medications for patients across China.-Fineline Info & Tech
